GlassScriptPhysician profile
Jack David Coorts
NPI 1457884074
$16,045.00
in general payments reported to CMS, 2019-2025
12 companies · $4,492 in 2025
The $4,492 reported for 2025 was more than what 90% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.84 · 2021: $348 · 2022: $2,190 · 2023: $310 · 2024: $8,661 · 2025: $4,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,887 · Travel and Lodging: $5,526 · Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,887.01 |
| Travel and Lodging | $5,525.84 |
| Food and Beverage | $2,049.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,492.05 | 2022-2024 | |
| Davol INC. | $3,529.17 | 2022-2025 | Phasix Mesh |
| Medical Device Business Services, INC. | $3,228.62 | 2021-2025 | Linx Reflux Management System, Stratafix |
| Ethicon US, LLC | $388.84 | 2020-2025 | Linx Reflux Management System, Echelon; Endopath, Echelon Flex |
| Stryker Corporation | $122.72 | 2023 | 1788 |
| Baxter Healthcare | $97.18 | 2022 | |
| Teleflex LLC | $45.04 | 2025 | Quikclot |
| Philips North America LLC | $43.49 | 2021 | |
| Tela Bio, INC. | $42.39 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Vertex Pharmaceuticals Incorporated | $21.26 | 2025 | |
| Atricure, INC. | $18.49 | 2022 | |
| Angiodynamics, INC. | $15.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Coorts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.